Last reviewed 2026-05-31 · How we verify

Triptolide Analog

City of Hope Medical Center · Phase 1 active Small molecule ✓ Verified May 2026

Triptolide Analog is a Small molecule drug developed by City of Hope Medical Center. It is currently in Phase 1 development. Also known as: Minnelide.

Triptolide Analog is a small molecule intervention being studied in clinical trials for various stages of lung cancer, including Advanced Lung Non-Small Cell Carcinoma and Stage III Lung Cancer. It is being tested alongside other treatments, such as Osimertinib, in combination with biopsy procedures.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Triptolide Analog
Also known as	Minnelide
Sponsor	City of Hope Medical Center
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Triptolide Analog CI brief — competitive landscape report
Triptolide Analog updates RSS · CI watch RSS
City of Hope Medical Center portfolio CI

Frequently asked questions about Triptolide Analog

What is Triptolide Analog?

Triptolide Analog is a Small molecule drug developed by City of Hope Medical Center.

Who makes Triptolide Analog?

Triptolide Analog is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

Is Triptolide Analog also known as anything else?

Triptolide Analog is also known as Minnelide.

What development phase is Triptolide Analog in?

Triptolide Analog is in Phase 1.

Manufacturer: City of Hope Medical Center — full pipeline
Also known as: Minnelide

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing